

가

20-25 Kg(23 Kg) 5 10 가 20 wattage 1 2 1 5 1 , 2 5 2 5 1 1 СТ

(HDI 5000, Philips Medical system, U.S.A.) CT (LightSpeed, General Electronic Medical Systems, Milwaukee, U.S.A.) T3, T4, TSH 7

(Ketamine; Yuhan, Seoul, Korea) 0.2 mg/kg 30 xylazine (Rumpun; Bayer Korea, Ansan, Korea) 0.1 cc/kg 30

. 5 - 12 MHz .

(ceftezole sodium, 20 mg/kg , ,) 200 wattage 500 kHz (Radionics, Massachusetts, U.S.A.) 17 gauge 1 가 cm 가 가 가 (Watson -

Marlow, Wilmington, Mass) 0.C 10 - 25 mL/min 가 20 - 30 . 가

. 10 wattage 20 wattage

1 , 2 , 3 , 4 , 5 5

20 wattage 1 2 . , 24 , 72 , 1 . 24 1 mm

:

, 24 , 72 , 1 СТ (lobitridol, Xenetix 300, Guerbet korea, Seoul, Korea) CT . 19 gauge 2 cc 0.625 mm, , pitch 0.938:1, (FOV) 14×14 cm 30 . CT СТ 2 가 7 T4, TSH T3,

5

. T3 (Diagnostic Products Corporation, Los Angeles, U.S.A.) , T4 (Institute of isotopes Ltd, Budapest, Hungary) , TSH (Radio - immunometric analysis) (Diagnostic Products Corporation, Los Angeles, U.S.A.)

> , 24 , 72 , 1 가 CT 가 , 가 , 기 , 기

(Ketamine; Yuhan, Seoul, Korea) 0.5 mg/kg xylazine (Rumpun; Bayer Korea, Ansan, Korea) 0.25 mg/kg

(succinyl choline; , ,) 200 mg/kg KCL (potassium chloride, Huons Co, Hwaseong, korea) 40 mg/kg

.

										1	3	2
	Н	ematoxylin - Eosin			3	24				1	2	2
	フ	· 가		2	2	-	가			1	1	
						1	1 2	2	-	71-	1	1
		٦L	, , ,				1 2	2		I		ст
		7										U1
,	, ,											
					1					1		3
				2	3	72				. 1	2	2
					2			. 2	1			
	, 24 , 72	, 1										
Та	ble 1 .			СТ	Г							
5	.1±0.3 mm,	8.2±0.2 mm,	28.2 ± 0.4			, 24	, 72	, 1	СТ			
mm	,	(Fig.	1A).		Tabl	e 3	,	,				
		1	2					СТ				
	٦L	I	2	/ =	ia 2/	^)		01				
	✓ Γ			٦) حت	ig. <i>zr</i>	۹).	_	1				
가		(Fig. 1B). 1	2	CT				ŀ				가
		가 가	(Fig. 1C)			, 1	2		가			
2			가 가									
				Tabl	e 2. N	Aean Size	e of the H	ypoech	oic Region	n of Th	yroid (Gland
24				in Do	ogs on	Ultrasou	ind Measu	ired at 2	4 Hours a	after RF	A	
	가		. 10	N	Jo.		group	1 (mm)		group	o 2 (mn	1)
					1		ç)			12	
			(Fig. 1D) 1		2		9)			11	
		04.05	(TIG. TD). T		3		1	0			11	
		9.4±0.5 mm	2 11.4±		4		9)			12	
0.5 mm	(Table 2).		1		5		1	0			11	
1	가	가					9.4 =	±0.5		11.4	4±0.5	
1	3 2	2		* gro	un 1 · '	20wattao	e 1 minut	e				

*group 1 : 20wattage, 1 minute *group 2 : 20 wattage, 2 minutes Abbreviation: RFA, radiofrequency ablation.

Table	1. US	Finding	of A	blated	Thy	roid '	Tissue	and	Com	plication	s
-------	-------	---------	------	--------	-----	--------	--------	-----	-----	-----------	---

72

24

			Group1						Group2			
		1	2	3	4	5	1	2	3	4	5	
Immediately	Thyroid echogenicity	hyper	hyper	hyper	hyper	hyper	hyper	hyper	hyper	hyper	hyper	
	perithyroidal echogenicity	inc	inc	inc	inc	inc	inc	inc	inc	inc	inc	
	Esophageal wall	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
	thickening or rupture											
After 24 H	Thyroid echogenicity	dec	dec	dec	dec	dec	dec	dec	dec	dec	dec	
	perithyroidal echogenicity	NC	inc	NC	NC	NC	NC	NC	NC	NC	NC	
	Esophageal wall	Wall	Wall	NA	NA	Wall	NA	Wall	NA	Wall	NA	
	thickening or rupture the	hickening	thickening			thickenin	g	thickening	t	hickenin	g	
After 72 H	Thyroid echogeni-city	NC	NC	NC	NC	NC	NC	NC	NC	NC	NC	
	perithyroidal echogenicity	dec.	dec.	NC	NC	dec.	dec.	dec.	dec.	NC	NC	
	Esophageal wall	dec.	NC	NA	NA	sus.	NA	NC	NA	nc	NA	
	thickening or rupture					rupture						
After 1 W	Thyroid echogenicity	NC	NC	NC	NC	NC	NC	NC	NC	NC	NC	
	perithyroidal echogenicity	dec	dec	NC	dec	NC	NC	dec	dec	NC	dec	
	Esophag-eal wall	NC	NC	NA	NA	NC	NA	NC	NA	sus.	NA	
	thickening or rupture									rupture		

inc: increased, dec: decreased, NC: no change, NA: not available, sus: suspicious

	CI	()	ig. 2B)	CI				
		7	가		5		1	ТЗ,
	. 1	2			T4가			. TSH
	1	2	가 .1	3	3			
2	2	(Fig. 2C, D)가			가		
		2	4					
	1	1 2	1					
	가				1	1	24	가
	72		СТ					가 (1/10).
			1 3 2 3	24				
	СТ	. 1	1					
	(Fig. 3).							. 1
	1		1	32			13±(0.1 mm, 7.2±0.2
	3 72	СТ	.1 2	2 2	mm	2	15.1 ± 0.1mm,	8.3±0.3 mm .
	가	. 2	1					

2 , 1



C

Fig. 1. US findings of a dog in group 2 treated by radiofrequency ablation (RFA).

A. Transverse US Image obtained prior to RFA shows hyper-echoic right thyroid gland.

B. US image obtained during RFA shows ill-defined hyperechoic foci in the right thyroid gland.

C. US image obtained at the 24 hours after RFA shows hypo-echoic pattern in the right thyroid gland (white arrow) as compared with normal thyroid tissue and increased echogenecity and thickening of fat tissue around right common carotid artery (arrowhead). Diffuse wall thickening of esophagus is also noted (black arrow).

D. Sagittal US image obtained at the 24 hours after RFA shows ill-defined hypoechoic area in the middle of the thyroid gland and the size of hypoechoic area is approximately 11mm in diameter.



Table 4. Complications Detected on Ultrasound or CT Scan and Pathologic Examination after RFA in the Thyroid Glands of Dogs

Complications	US or CT	Pathologic examination
Change of peri-thyroidal fat tissue	10	10
Thickening of esophageal wall	5	5
Perforation of esophagus	2	2

*Values are number.

Abbreviation: RFA, radiofrequency ablation.

Table 3. CT Findings of Ablated Thyroid Tissue and Complications

		Group1					Group2				
		1	2	3	4	5	1	2	3	4	5
Immediately	Thyroiddensity	low	low	low	low	low	low	low	low	low	low
	Perithyroidal infiltration	+	+	+	+	+	+	+	+	+	+
	Esophageal wall		Wall	Wall		Wall		Wall		Wall	
	thickening or ruptire	-	thickening	thickenir	1g -	thickening	-	thickening	-	thickening	-
After 24 H	Thyroid density	NC	NC	NC	NC	NC	NC	NC	NC	NC	NC
	Perithyr-oidal infiltration	NC	NC	NC	NC	inc	NC	NC	NC	inc	NC
	Esophag-eal wall thickening or ruptire	-	NC	NC	-	NC	-	NC	-	NC	NC
After 72 H	Thyroid density	NC	NC	NC	NC	NC	NC	NC	NC	NC	NC
	Perithyr-oidal infiltration	dec	dec	NC	dec	NC	dec	dec	dec	NC	NC
	Esophag-eal wall thickening or ruptire	-	NC	NC	-	rupture	-	NC	-	NC	NC
After 1 W	Thyroid density	NC	NC	NC	NC	NC	NC	NC	NC	NC	NC
	Perithyroidal infiltrati-on	dec	dec	NC	dec	NC	dec	dec	dec	NC	NC
	Esophageal wall thickening or ruptire	-	NC	NC	-	rupture	-	NC	-	rupture	NC

inc: increased, dec: decreased, NC: no change, NA: not available

С



D

Fig. 2. CT findings of a dog in group 2 treated by radiofrequency ablation (RFA).

A. CT Image obtained prior to RFA shows hyperdense normal thyroid gland (white arrow). Pre-enhancement (**B**) and post-enhancement CT image (**C**) obtained immediately after RFA shows decreased attenuation of right thyroid glands (white arrow), increased attenuation of fat tissue around both common carotid artery, and diffuse wall thickening of esophagus (black arrow).

D. Enhancement CT image obtained at the 24 hours after RFA shows no interval change as compared with Fig. 1C.

가



(15, 18)

1 cm







A

Fig. 3. CT findings of a dog in group 1 complicated by the perforation of esophageal wall.

A. Pre-enhancement CT scan prior to radiofrequency ablation (RFA) shows normal hyper-dense thyroid glands (white arrow).

B. Enhancement CT scan obtained immediately after RFA shows slightly low attenuation of both thyroid glands (white arrow), mild increased attenuation of peri-thyroidal fat tissue, and diffuse wall thickening of esophagus (black arrow).

C. Enhanced CT scan obtained 24 hours after RFA shows decreased wall thickening of esophagus and otherwise shows no interval change.

D. Enhancement CT scan 72 hours after RFA shows left esophageal perforation (white arrow).

Α





Fig. 4. CT and histopathologic findings of a dog in group 1 complicated by the right recurrent laryngeal nerve palsy.

A. Pre-enhancement CT scan obtained prior to radiofrequency ablation (RFA) shows normal hyper-dense thyroid glands (arrow).

B. Enhancement CT scan obtained 24 hours after RFA shows mild wall thickening of esophagus and increased attenuation (arrows) of peri-thyroidal fat tissue which the right side was more severe than the left side.

C. Photograph (Hematoxylin-eosin stain; original magnification, $\times 10$) shows coagulation necrosis of right thyroid gland (arrowheads) and nerves (arrows) in the peri-thyroidal fat tissue.

D. Photograph (Hematoxylin-eosin stain; original magnification, $\times 100$) shows coagulation necrosis of the nerve adjacent to right thyroid gland.

가

	148	3 cm	CT	
	30		, CT 1	
12		(18)	СТ	
		가		
		3	가	
		가	. CT	
Suggitani	Fuiimoto (1	5) 1995		
21		-,	17 gauge	
3		71		
71		-1	71	
~1			~1	
		1 am		
,	(40, 44)	1 cm	, ⁷ r ⁷ r	
	(13, 14)	•	(0 -)	
			(25).	
		_1	1 2 2	
		가 .	가	
		가	, 1 2 가	
가		. , 10	5 가,	
가		,		
		가	가 가	
		가		
		(15).	가.,	
			가	
	(3, 4).		, СТ	
			. ,	
			CT가	
			1 가	
		(19 - 23)	가 CT	
			가 가	
가		(24).		
Pa	cella			
			가 가	
(25).			2	
		가	1 1 1	
			. CT	
			가	
			가 .	
가				
		-	가 가	
(26)	,			
().			1 2 1 72 1	
		CT		
	24	0.		

339



- Hall TL, Layfield LJ, Philippe A Rosenthal DL. Sources of diagnostic error in fine needle aspiration of thyroid. *Cancer* 1989;63:718-725
- Rojeski MT, Gahrib H. Nodular thyroid disease: evaluation and management. N Engl J Med 1985;313:428-436
- Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. *Ann Intern Med* 1997;126:226-231
- Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. *Thyroid* 1998;8: 15-21
- Nunez C, Mendelsohn G. Fine-needle aspiration and needle biopsy of the thyroid gland. *Pathol Annu* 1989;24:161-198

- Gikas PW, Labow SS, DiGiulio W, Finger JE. Occult metastasis from occult papillary carcinoma of the thyroid. *Cancer* 1967;20: 2100-2104
- Kasai N, Sakamoto A. New subgrouping of small thyroid carcinomas. *Cancer* 1987;60:1767-1770
- Scholler P, Heber S, Hoheisel JD. Optimization and automation of fluorescence-based DNA hybridization for high-throughput clone mapping. *Electrophoresis* 1998;19:504-508
- Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmo, Sweden. *Cancer* 1981;47:319-323
- Bondeson L, Ljungberg O. Occult papillary thyroid carcinoma in the young and the aged. *Cancer* 1984;53:1790-1792
- Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A" normal "finding in Finland. A systematic autopsy study. *Cancer* 1985;56:531-538
- Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. *Histopathology* 1993;23:319-325
- Maruchi N, Furihata R, Makiuchi M. Population surveys on the prevalence of thyroid cancer in a non-endemic region, Nagano, Japan. Int J Cancer 1971;7:575-583
- Pelizzo MR, Piotto A, Rubello D, Casara D, Fassina A, Busnardo B. High prevalence of occult papillary thyroid carcinoma in a surgical series for benign thyroid disease. *Tumori* 1990;76:255-257
- Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. *Endocr J* 1999;46:209-216
- Furlan JC, Bedard Y, Rosen IB. Biologic basis for the treatment of microscopic, occult well-differentiated thyroid cancer. *Surgery* 2001;130:1050-1054
- Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. *Cancer* 2003;98:31-40
- Sugitani I, Yanagisawa A, Shimizu A, Kato M, Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg 1998;22:731-737
- Livraghi T, Paracchi A, Ferrari C, Reschini E, Macchi RM, Bonifacino A. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: preliminary results. Work in progress. *Radiology* 1990;175:827-829
- Livraghi T, Paracchi A, Ferrari C, Reschini E, Macchi RM, Bonifacino A. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: 4-year experience. *Radiology* 1994; 190:529-533.
- 21. Monzani F, Del Guerra P, Caraccio N, Casolaro A, Lippolis PV, Goletti O. Appearance of Graves ' disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma. *J Endocrinol Invest* 1997;20:294-298
- 22. Zingrillo M, Torlontano M, Ghiggi MR, Frusciante V, Varraso A, Liuzzi A, et al. Radioiodine and percutaneous ethanol injection in the treatment of large toxic thyroid nodule: a long-term study. *Thyroid* 2000;10:985-989
- 23. Del Prete S, Russo D, Caraglia M, Vitale G, Giuberti G, Marra M, et al. Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40 ml: three years of follow-up. *Clin Radiol* 2001;56:895-901
- Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. *Endocr Rev* 2003;24:102-132

- Pacella CM, Bizzarri G, Spiezia S, Bianchini A, Guglielmi R, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. *Radiology* 2004;232:272-280
- Wood BJ, Ramkaransingh JR, Fojo T, Walther MM, Libutti SK. Percutaneous tumor ablation with radiofrequency. *Cancer* 2002; 94:443-451

J Korean Radiol Soc 2005;52:333 - 341

Ultrasound-Guided Radiofrequency Ablation of Thyroid Gland: A Preliminary Study in Dogs¹

Ji Won Choi, M.D., Seo-Hyun Kwak, M.D.², Seung Min Yoo, M.D., In Sup Song, M.D., Hwa Yeon Lee, M.D., Jong Beum Lee, M.D., Hyung Jin Shim, M.D., Byung Kook Kwak, M.D., Yang Soo Kim, M.D., Yong Chul Lee, M.D., Kun Sang Kim, M.D., Tae Jin Lee, M.D.³

> ¹Department of Diagnostic Radiology, College of Medicine, Chung-Ang University ²Department of Diagnostic Radiology, Seoul Veterans Hospital ³Department of Pathology, College of Medicine, Chung-Ang University

Purpose: The purpose of this study was to evaluate the possibility of using radiofrequency ablation as the treatment modality for the benign or malignant thyroid nodules in humans. Therefore, we examined the results of using radiofrequency ablation on the thyroid glands in dogs, in respect of the extent of the ablated tissue and the complications.

Materials and Methods: Five dogs (10 lobes of the thyroid glands) were included in this study. US-guided radiofrequency ablation was undertaken with a 10mm, uncovered 17 gauge cool-tip needle. The power and duration was 20 wattage and 1 minute in five thyroid lobes (group 1) and 20 wattage and 2 minutes in another 5 thyroid lobes (group 2). The ultrasound scans and the pre-and post-enhancement CT scans were undertaken before and immediately after the procedures, and at 24 hours, 72 hours and 1 week later. The US and CT findings of the ablated tissue and complications were evaluated. Blood sampling was done at the pre-procedure time and 1 week later for evaluating the functional status of the thyroid gland. Laryngoscopy was done at the pre-procedure and post-procedure times, and at 24 hours, 72 hours and 1 week later for the evaluation of any recurrent laryngeal nerve palsy.

Results: The echo pattern of the ablated thyroid gland at immediately after the radiofrequency ablation appeared as poorly marginated and hyperechoic. On the US obtained 24 hours after radiofrequency ablation, the echo pattern of the ablated thyroid gland was hypoechoic. The maximum diameters after RFA were 9.4 ± 0.5 mm in group I and 11.4 ± 0.5 mm in group II. The pre-enhanced CT scan taken at immediately after the radiofrequency ablation showed ill defined hypodense areas in the ablated thyroid gland. Differentiation between the normal and abnormal portions of the thyroid gland was difficult on the contrast enhanced CT scan. Complications induced by radiofrequency ablation were one recurrent laryngeal nerve palsy, two perforations of esophagus and five thickenings of the esophageal wall. In summary, the radiofrequency ablation therapy for the benign or malignant thyroid nodules located in anterior aspect (within a 5 mm radius) of the thyroid gland in human suggests this is an effective treatment, through this was an animal study performed on dogs.

Index words : Thyroid neoplasms Radio-frequency ablation Papillary micro-carcinoma Thyroid ablation

Address reprint requests to : Seo-Hyun Kwak, M.D., Department of Diagnostic Radiology, Seoul Veterans Hospital, 6-2 Dunchon2-dong, Kangdong-gu, Seoul 134-791, Korea. Tel. 82-2-2225-1426 Fax. 82-2-2225-1488 E-mail: board777@hanmail.net